Cord blood cells join fight against transplant complication

NCT ID NCT04744116

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated May 01, 2026 · Updated 15 times

Summary

This early study tests whether adding special cells from donated cord blood to a standard drug (ruxolitinib) can better control a serious immune reaction called graft-versus-host disease (GVHD) that does not respond to steroids. The study includes 24 people aged 12 to 80 who have this condition after a stem cell or bone marrow transplant. Researchers will compare the combination treatment against ruxolitinib alone to see if it improves response and reduces side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM STEROID REFRACTORY GRAFT VERSUS HOST DISEASE